M. Hornberger

Discovery of highly potent heme-displacing IDO1 inhibitors based on a spirofused bicyclic scaffold.

Michael Albers, O. Kinzel, Thomas Hoffmann, 2020, Bioorganic & medicinal chemistry letters.

Discovery and Optimization of substituted Oxalamides as novel heme-displacing IDO1 Inhibitors.

Michael Albers, O. Kinzel, Thomas Hoffmann, 2020, Bioorganic & medicinal chemistry letters.

Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.

U. Deuschle, T. Schlüter, C. Kremoser, 2010, Bioorganic & medicinal chemistry letters.

Structure-specificity relationship of cardiac glycosides as a substrate for glucohydrolase II.

W. Kreis, M. Hornberger, Y. Terada, 2000, Chemical & pharmaceutical bulletin.

The nuclear bile acid receptor FXR controls the liver derived tumor suppressor histidine‐rich glycoprotein

U. Deuschle, C. Kremoser, O. Kinzel, 2015, International journal of cancer.

Discovery of Hydroxyamidine Based Inhibitors of IDO1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation.

O. Kinzel, Thomas Hoffmann, S. Anderhub, 2020, ACS medicinal chemistry letters.

Demonstration of antiinflammatory activity of fibrinogen and fibrinopeptides in rats

G. Ruhenstroth-Bauer, M. Hornberger, R. Scherer, 1981, Inflammation.

Aroma Evolution during Flower Opening in Rosa damascena Mill

N. Watanabe, K. Sakata, M. Hornberger, 1999 .

Purification and characterisation of the cardenolide-specificβ-glucohydrolase CGH II from Digitalis lanata leaves

W. Kreis, M. Hornberger, Ute Böttigheimer, 2000 .

Renal fibrosis is the common feature of autosomal dominant tubulointerstitial kidney diseases caused by mutations in mucin 1 or uromodulin.

M. Uder, A. Ekici, C. Antignac, 2014, Kidney international.

Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany.

K. Zerres, C. Eng, C. Jilg, 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties.

U. Deuschle, T. Schlüter, C. Kremoser, 2016, Bioorganic & medicinal chemistry letters.